Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05757700 | Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma | PHASE1 | ACTIVE NOT_RECRUITING | 30 | — | — | Feb 23, 2023 | Feb 23, 2027 | Apr 22, 2026 | 1 | United States |
The target toxicity rate for the MTD is
| Arm | Type | Description |
|---|---|---|
| Participants with Diffuse Large B-Cell Lymphoma (DLBCL) and large B cell lymphoma | EXPERIMENTAL | Participants have histologically confirmed DLBCL and large B cell lymphoma. Participants will be treated with escalating doses of modified T cells. |
| Name | Type | Description |
|---|---|---|
| 19(T2)28z1xx TRAC T cell | BIOLOGICAL | Participants will be treated with escalating doses of modified T cells. Dose level -1: 3 x 10\^6 Dose level 1: 10 x 10\^6 Dose level 2: 30 x 10\^6 Dose level 3: 100 x 10\^6 |
Inclusion Criteria: * Age ≥ 18 years of age * Creatinine ≤1.5 mg/100 ml or creatinine clearance ≥ 45ml/min/m2 , direct bilirubin ≤2.0 mg/100 ml, AST and ALT ≤3.0x upper limit of normal (ULN) * Adequate pulmonary function as assessed by ≥92% oxygen saturation on room air by pulse oximetry. * Histolo...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Soligenix, Inc. | SNGX | 1 | PHASE3 | Hypericin |
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib, Pembrolizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | — | Undisclosed |